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ABSTRACT (max 150 words)

Cardiovascular disease (CVD) is higher in people with mental illness and is associated with a
30 year higher mortality rate in this population. Erythrocyte docosahexaenoic acid (DHA)
plus eicosapentaenoic acid (EPA) (omega-3 index) ≤ 4% is a marker for increased mortality
risk from CVD while >8% is protective. Omega-3 polyunsaturated fatty acids are also
important for brain function and may ameliorate symptoms of mental illness. We investigated
the erythrocyte omega-3 index in people with mental illness. One hundred and thirty adults
aged 18-65 years (32.6% male) with schizophrenia (n=14) and depression (n=116) provided
blood samples and completed physiological assessments and questionnaires. Both
populations had risk factors for metabolic syndrome and CVD. The average omega-3 index
was 3.95% (SD=1.06), compared to an estimated 5% in the Australian population. These data
indicate an unfavourable omega-3 profile in people with mental illness that could contribute
to higher CVD risk.

Keywords: polyunsaturated fatty acids, omega-3, omega-3 index, mental illness, depression,
schizophrenia, cardiovascular disease
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INTRODUCTION
In 2001 the World Health Organisation reported that around 450 million people worldwide
suffered from a mental health problem and that one in four people will experience mental
illness at some stage in their life [1]. Recent findings from the World Health Organisation’s
World Mental Health survey identified that mental disorders are common across 28
participating countries, with an interquartile range from 18.1-36.1 per cent of lifetime
prevalence [2]. Like physical health, mental health is a complex interaction of biological,
psychological and social factors [1]. Not only does chronic mental illness lead to substantially
reduced quality of life, social and economic burden, it is compounded by high rates of
physical illness. People with serious mental illness (SMI) are more likely to suffer from a
range of physical health problems, particularly metabolic syndrome/diabetes and
cardiovascular disease (CVD) [3-6]. Behavioural factors that lead to poor lifestyle choices
such as smoking, diet and low physical activity contribute to this higher risk [1, 7]. Although
medications also contribute to CVD risk factors, lifestyle factors such as poor diet (e.g. low
fibre, high fat, high sugar) have been identified as independent contributors [8-10].

These lifestyle behaviours may contribute to common underlying biological mechanisms for
both physical and mental illness and their comorbidities [11]. Supporting evidence comes
from a meta-analysis of epidemiological studies showing a significant association between
depression and metabolic syndrome [6], a cluster of risk factors for CVD including
hyperglycemia and/or insulin resistance, hypertension, abdominal adiposity and
hyperlipidemia. Interestingly, prospective studies identified in the latter review showed that
the association is bidirectional. Another meta-analysis showed that depressed adults have a
37% increased risk of developing diabetes [5]. These studies provide evidence that people
don’t develop depression as a result of being physical ill, and that in fact there may be
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underlying mechanisms that manifest as mental illness before symptoms of physical illness
become apparent.

One of the possible common contributors to both cardiometabolic and mental health is the
group of omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs). The benefits of n-3
LCPUFA for cardiovascular health have been well established [12] (despite recent studies
which are plagued by methodological issues, largely associated with the fact that they were
conducted after 2000 and 2002 American Heart Foundation recommendations for increased
fish and fish oil intake respectively, and subsequent exponential increase in fish oil imports
[13, 14]). Mechanisms for reducing CVD risk may include reduction of ventricular
arrhythmia, thrombosis, triglycerides, atherosclerotic plaque, inflammation and hypertension,
and endothelial relaxation [15]. Based on the body of evidence, an omega-3 index for
cardiovascular health was developed by Harris and von Schacky [16]. They first established
erythrocyte levels of the long chain n-3 LCPUFAs eicosapentaenoic acid (EPA; 20:5n-3) plus
docosahexaenoic acid (DHA; 22:6n-3) as a valid biomarker of omega-3 status. Then by
pooling together results from a body of large prospective and randomised controlled trials
they identified that a combination of EPA plus DHA levels of ≤ 4% in erythrocyte
membranes was associated with the highest risk of mortality from coronary heart disease
(CHD) whereas levels ≥ 8% conferred the greatest cardioprotection. Therefore the omega-3
index was proposed as a useful biomarker to estimate risk of mortality from CHD and
provide targets for reducing mortality risk.

Since the prevalence of n-3 LCPUFA DHA in brain tissue was discovered in the 1970s [17] a
number of pivotal roles have been identified for DHA in brain function, including a key
structural role in brain cells and phospholipids, neurite growth, membrane fluidity,
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neurotransmission (e.g. synthesis of neurotransmitters serotonin and dopamine), endothelial
function and brain barrier integrity, neuronal survival and protection from neurodegeneration
[18]. The role of EPA and DHA in improving endothelial function via production of antiinflammatory eicosanoids, reducing adhesion of substances to the endothelial wall and
influence on nitric oxide production (and therefore vasodilation and blood flow) may
contribute to common underlying mechanisms for their protective role in cardiovascular and
mental health [19]. A growing body of work has investigated the role of n-3 LCPUFAs in
mental health with indications of benefit across the lifespan including developmental
disorders, depression, schizophrenia and cognitive decline [20, 21]. Following the latter
studies reviewed, a robust multi-centre trial reported that n-3 LCPUFA supplementation for
12 weeks was able to significantly reduce transition to psychosis at 12 month follow-up
compared to placebo in young people at high risk for psychosis [22]. We previously proposed
an omega-3 index for mental health although there were as yet insufficient blood fatty acid
data to establish this [23].

Inflammation has been proposed as a possible mediating role for comorbid physical and
mental illness [24-28] and may be one of the mechanisms by which n-3 PUFA exert their
effects. The anti-inflammatory properties of eicosanoids produced by EPA counteract the
largely inflammatory properties of eicosanoids produced by arachidonic acid (AA) from the
n-6 PUFA series. The n-3 and n-6 PUFA series compete for the same enzymes for elongation
and desaturation, and a higher intake of one can displace the other in cell membranes. This is
of concern in Western societies that have increased the intake of n-6 PUFA via vegetable oils
and processed foods while decreasing intake of n-3 PUFA from nuts, seeds, dark leafy
vegetables and fatty fish, including Australia [29, 30]. It has been proposed therefore that the
ratio of n-6/n-3 PUFAs, which in Western diets is estimated at 15-16/1 (8/1 in Australia [30])
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compared to an equal ratio in traditional diets, contributes to pro-inflammatory states that
underlie chronic illness [31].

In the present study we investigated erythrocyte PUFA levels in people with SMI to
determine their erythrocyte omega-3 index and associations with physical and mental health.
This study utilised baseline data from two related studies: a pilot study with residents of a
Community Rehabilitation Centre for people with serious mental illness and a randomised
controlled trial with community dwelling people suffering from depression.

METHOD
Study 1 was a partnership between the University of South Australia and the Mental Health
Directorate in the Southern Adelaide Local Health Network. Ethics approval was obtained
from the Southern Adelaide Clinical Human Research Ethics Committee (HREC) and the
HREC at the University of South Australia. For study 2 community dwelling adults suffering
depressive symptoms were recruited, for which ethics approval was provided by the HREC at
the University of South Australia. Both studies aimed to investigate the effect of a
Mediterranean-style diet and fish oil supplementation on cardiometabolic and mental health
(HELFIMED: Healthy Eating for Life with a Mediterranean-style Diet), the first as a pilot
feasibility study [32] and the second as a randomised controlled trial [33]. This report utilises
baseline data from those studies. For study 1 information sessions were conducted to explain
the project to staff and residents of a Community Rehabilitation Centre (CRC) with 20 beds
for people with serious mental illness. The population is transient with an average stay of
around 9 months. Ongoing recruitment was undertaken for the pilot feasibility study from
May 2013 to February 2014 and was open to all new residents entering the CRC during that
time. All consenting residents were eligible to take part. For study 2 we recruited community
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dwelling people via newspaper advertisements, media releases, social media and a
recruitment agency. Inclusion criteria were depressive symptoms over the past 3 months or
more, age between 18-65, poor diet according to an adapted dietary screening tool and not
consuming fish oil supplements over the past 3 months.

Participants
Over an 8-month period, 25 CRC residents aged 18-59 years with schizophrenia signed up
for study 1 and completed baseline assessments. In the first batch of blood samples many
were oxidised due to an inappropriate protocol for washing of the red blood cells which was
then rectified. Therefore, 14 blood samples were available for analysis of erythrocyte fatty
acids. In study 2, 164 participants aged 18-65 completed baseline assessments. Of those, 116
people had either diagnosed depression (n=75; 58%) and/or depressive symptoms in the
‘severe’ or ‘extremely severe’ range on the Depression, Anxiety, Stress scale (DASS-21) [34]
and are included in these analyses. Summary characteristics are provided in Table 1.

Assessments
Baseline assessments included fasted blood samples, weight, height, waist circumference and
blood pressure, and the following questionnaires: the Assessment of Quality of Life (AQoL)8D scale [35] in both studies and the DASS-21 [34] and Positive and Negative Affect Scale
(PANAS) in study 2. These are described below. A background questionnaire measured the
following potential covariates: age, gender, socio-economic status (Socio-Economic Indexes
for Areas decile), education level (1=completed primary school; 8=postgraduate degree),
household income, physical activity (calculated as total minutes per week), smoking status
(1=never smoked; 5=smoke daily), and frequency of consuming >2 alcoholic drinks per day
(1=never/rarely; 5=daily).
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Fatty acids
Fasted blood samples were collected by trained phlebotomists in 6ml EDTA tubes. Red blood
cells were separated from plasma by low speed centrifugation and packed red blood cells
were stored in 1ml micro tubes at -80C until analysis. Erythrocyte samples were thawed and
prepared for fatty acid analysis according to Swierk et al [36] using the direct
transesterification procedure according to Lepage and Roy [37]. Samples were analysed by
flame-ionisation gas chromatography (model GC-17A, Shimadzu) using a 50m x 0.25mm
internal diameter capillary column. One microlitre of the sample was auto-injected into the
column, and individual fatty acids were quantified using the Shimadzu analysis software
(Class-VP 7.2.1 SP1, USA). Fatty acid peaks were identified by comparison with known fatty
acid standards and quantitated by comparison to the 21:0 internal standard (Nu-chek and
Sigma). Erythrocyte EPA plus DHA as a percent of cell membranes was calculated to obtain
the omega-3 index as reported by Harris and von Schacky [16].

AQoL-8d
The AQoL-8d is a 35-item questionnaire that is used to measure quality of life. The 35 items
load onto eight dimensions, of which three represent physical domains of quality of life
(independent living, pain and senses) and five represent psychological domains (happiness,
self-worth, coping, relationships, mental health). These load onto two super dimensions
(physical and psycho-social). The scores from each dimension are combined to create a final
AQoL-8D utilities score for use in economic evaluation studies. The AQoL-8D has good
validity and internal consistency with alpha coefficients of 0.89-0.96 [38].

DASS-21
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The DASS is a 21-item self-report scale which provides a measure of the level of negative
emotional states of depression, anxiety and stress. It is a highly reliable measure that shows
high convergent validity and has good internal consistency with a Cronbach alpha of 0.820.93 [34, 39] Ronk et al. 2013). DASS-21 sub-scale severity ratings are calculated based on
the full DASS-42 severity rating [40]. The scale was multiplied by two and divided into the
severity categories to yield equivalent scores ranging from 1-5. Those with severity ratings of
4 and 5 (severe and extremely severe; study 2) are included in this study.

PANAS
The PANAS is a 20-item scale measuring positive and negative emotions. It has been
validated and demonstrates reliable psychometric properties, discriminant, convergent and
constructed validity. The reliability (internal consistency) of the PANAS positive and
negative emotions scales were determined to be α =.89 and .85 respectively [41].

Statistical analysis
Descriptive statistics were used to identify the omega-3 index, demographic, cardiovascular
and mental health parameters. Pearson correlations were used to investigate bivariate
associations between the omega-3 index, mental and cardiometabolic health outcome
measures. For any significant associations between the omega-3 index and physical or mental
health, potential covariates that were significantly associated with outcome variables were
planned to be entered into regression analyses to control for these. Significance for
correlations was set at P < 0.01 to allow for multiple comparisons.

RESULTS
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As can be seen in Table 1, average data for each sample show that both samples had CVD
risk factors with BMI in the obese range, central adiposity, elevated blood pressure for
participants in study 2 and slightly elevated fasting glucose in the study 1 sample. The
average omega-3 index for the whole sample was 3.95% (SD = 1.06) of erythrocyte
membranes. The majority (56%) of participants had an omega-3 index in the high risk range
≤ 4%, and the remaining 44% in the medium risk range from 4-8% (with only 6 participants
or 4.6% with an omega-3 index > 6%). No participants had an omega-3 index ≥ 8%, the
range that confers highest protection against mortality from CVD. Participant data are broken
down by group in Table 1 and the distribution of the omega-3 index is shown in Figure 1.

Figure 1: Distribution of the omega-3 index
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Table 1: Summary characteristics, omega-3 index, omega-6 and omega-3 polyunsaturated
fatty acid levels of study participants (N=130)
Reference range

CRC
n

Mood Study

M (SD)

M (SD)

n

Age

n/a

14

29.00 (11.29)

118

43.90 (13.07)

Gender

n/a

14

71.4% male

118

28% male

Fasting blood glucose

4-6 mmol/L

11

6.15 (0.95)

-

N/A

Waist circumference (male)

< 94 cm

9

107.78 (22.58) 31

102.67 (19.71)

Waist circumference (female)

< 80 cm

3

91.33 (13.43)

81

93.72 (19.82)

BMI (weight/height2)

18.5-25

10

30.97 (6.53)

112

30.77 (8.13)

111

80.06 (10.25)

[> 30 = obese]
Diastolic blood pressure

< 80 mmHg

9

74.83 (9.09)

Systolic blood pressure

< 120 mmHg

9

112.44 (11.58) 111

120.98 (15.42)

Omega-3 index

≤ 4% ↑ risk; ≥ 8% 14

4.04 (0.63)

3.92 (1.09)

(EPA + DHA)

↓ risk for CVD

116

mortality
CRC = Community Rehabilitation Centre (participants with schizophrenia); Mood Study =
community dwelling participants with diagnosed depression and/or severe/extremely severe
depression scores on the 21-item Depression Anxiety Stress Scale (DASS-21).

Pearson correlations between the omega-3 index, mental health and health-related quality of
life are shown in Table 2. There were no significant associations between the omega-3 index
and mental health, quality of life or cardiometabolic health outcomes. Therefore it was not
possible to run regression analyses as planned.

Table 2: Pearson correlations between erythrocyte fatty acids, mental health and healthrelated quality of life, N=116-130†
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Omega-3 index
Depression (DASS)

-0.058

Anxiety (DASS)

-0.048

Stress (DASS)

-0.144

Positive affect (PANAS)

0.084

Negative affect (PANAS)

-0.001

AQoL Independent living

0.119

AQoL Happiness

0.024

AQoL Mental health

0.026

AQoL Coping

-0.004

AQoL Relationships

-0.011

AQoL Self worth

0.140

AQoL Pain

-0.017

AQoL Senses

-0.080

AQoL Super dimension psycho-social

-0.013

AQoL Super dimension physical health

0.020

Systolic blood pressure (mmHg)

-0.068

Diastolic blood pressure (mmHg)

-0.045

Body mass index (BMI; h/m2)

-0.117

Waist circumference

-0.021

Apolipoprotein B/A1 ratio

0.049

*p < 0.05; **p < 0.01. †N varies due to missing data on individual subscales and/or some
scales only completed by Mood Study cohort. DASS = Depression, Anxiety, Stress Scale
(21-item); PANAS = Positive And Negative Affect Scale; AQoL = Assessment of Quality of
Life 8-d scale
12

DISCUSSION
In this study we analysed PUFA data from people with SMI, i.e. schizophrenia and severe
depressive symptoms, and determined their overall omega-3 index to be less than 4% which
is in the range that has been identified as high risk for mortality from CVD [16]. We know
that n-3 PUFA intake in Western societies is low generally, and this could be a contributor to
the high global mortality from CVD [42]. The average omega-3 index in the Australian
population is 5% [36, 43]. In our population of people with mental illness, the omega-3 index
is even lower, potentially placing them at greater risk for mortality from CVD. Consistent
with this, our sample of people with mental illness had, on average, risk factors for metabolic
syndrome and CVD including elevated blood glucose, BMI in the obese range and excessive
abdominal adiposity. However these did not correlate with the omega-3 index. A review by
von Schacky reported an omega-3 index of between 2.90-7.15% in a range of populations in
western countries (with high incidence of CHD) and 3.47-12.83% in Asian countries (with
low incidence of CHD). In all studies low omega-3 index was associated with a worse health
condition. In addition to those cited in the review, a Korean study reported an omega-3 index
of 8.83% in patients with acute STEMI compared to 11.13% in healthy controls, and the
omega-3 index was inversely associated with the odds for being a STEMI patient [44]. A
meta-analysis by Lin et al reported lower EPA and DHA in depressed patients than controls
(actual levels not reported). McNamara et al. found a lower omega-3 index in American
patients with major depressive disorder (3.8% ± 0.2) and bipolar disorder (3.3% ± 0.2)
compared with healthy controls (4.8% ± 0.3) [45].

As outlined earlier, a number of mechanisms have been identified for the roles of n-3
LCPUFA in the brain [18, 21] that include potentially vascular mechanisms which may
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underlie both cardiovascular and mental health [19]. Further supportive of this, Canadian
researchers investigated n-3 PUFA levels in people who had suffered an acute myocardial
infarction and found that those who suffered major depression had notably lower n-3 PUFA
levels and omega-3 index (4.46%) than those without depression (5.05%) [46]. Another very
interesting study showed in a rat model that a high fructose drink increased triglycerides and
insulin resistance in the brain, and that this effect was attenuated with an n-3 rich diet.
Furthermore, increased insulin resistance and triglyceride levels were associated with poorer
performance on a cognitive task. The authors suggested that this may provide evidence of
metabolic syndrome in the brain, which is exacerbated by n-3 PUFA deficiency [47].
Therefore there may be utility in translation of the omega-3 index from cardiovascular to
mental health.

Similarly to McNamara et al. [45], and as with our cardiometabolic health outcomes, there
were no associations between the omega-3 index and mental health or quality of life. This
may be either because there is no association with the measures used in the sample or because
these n-3 PUFA levels were too low across the population. This would need to be
investigated further in a sample with greater variability in omega-3 levels, across the low and
high risk range for mortality from CHD.

The low levels of n-3 LCPUFAs EPA and DHA in this sample of people with mental illness
and CVD risk factors is of concern. Given the role of these PUFAs in cardiovascular and
mental health, this is an issue that requires further consideration in terms of developing a
strong evidence base for translation into policy and practice. The direct roles of n-3
LCPUFAs, particularly DHA, in brain function and growing evidence of their ability to
reduce symptoms of mental illness suggest that an omega-3 index or its equivalence might
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similarly provide a useful target for estimating risk of mental illness and targets for treatment.
As well as being a good indicator of n-3 PUFA levels in cardiac tissue, erythrocyte levels
correspond to those found in brain tissue [48]. More studies are needed to establish baseline
erythrocyte n-3 and n-6 PUFA levels that are associated with highest risk of mental illness,
and correlate increased levels following n-3 PUFA supplementation with improved mental
health outcomes to determine levels that are associated with greatest protection. It would be
useful for intervention studies to be conducted over at least 6 months to enable maximum
saturation of cell membranes [49], recruit people with low omega-3 index with the aim of
reaching the target range (> 8%) [42] and to identify critical periods that provide maximum
opportunity for prevention, e.g. in teenage years for young people at high risk for psychosis,
when n-3 PUFA supplementation appears to provide optimal protection against transition to
psychosis [22].

In conclusion, the omega-3 index was very low in this population of people with SMI. This is
of concern given the associations between such a low omega-3 index and increased risk of
mortality from CVD.
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